Zinger Key Points
- Sonoma received U.K. regulatory clearance for its key wound care and dermatology products.
- The newly approved products include the company's hypochlorous acid-based wound irrigation solution and scar management products.
- The new Benzinga Rankings show you exactly how stocks stack up—scoring them across five key factors that matter most to investors. Every day, one stock rises to the top. Which one is leading today?
Sonoma Pharmaceuticals, Inc. SNOA stock is trading higher on Tuesday after the company announced that it secured U.K. regulatory clearance for its key wound care and dermatology products.
The Details: Sonoma received clearance from the Medicines & Healthcare products Regulatory Agency for five products, including its hypochlorous acid-based wound irrigation solution, scar management products, wound hydrogel and skin exfoliant.
“Thanks to the diligent efforts of our regulatory team in securing these new registrations with the MHRA, we are now able to bring our safe and effective Microcyn-based products to the United Kingdom,” said Amy Trombly, CEO of Sonoma.
“The U.K. represents a significant new market for Sonoma, for both our wound care and dermatology products, and we are excited for the opportunities for growth that this new registration provides.”
See Also: Why Is Jeffs Brands Surging Premarket On Tuesday?
SNOA Price Action: At the time of writing, Sonoma shares are trading 17.6% higher at $3.24, according to data from Benzinga Pro.
Image: This illustration was generated using artificial intelligence via Midjourney.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.